AMPLIFY-201, a first-in-human safety and efficacy trial of adjuvant ELI-002 2P immunotherapy for patients with high-relapse risk with KRAS G12D-or G12R-mutated pancreatic and colorectal cancer.

Authors
Category Primary study
JournalJOURNAL OF CLINICAL ONCOLOGY
Year 2023
This article has no abstract
Epistemonikos ID: 8d54187c07cc46d2e6c63f44fba4667dfd7fa840
First added on: Feb 19, 2025